Halofantrine

Antimalarial medication

Halofantrine
Halofantrine Chemical structure of Halofantrine

Halofantrine is an antimalarial drug used for the treatment of malaria, a disease caused by Plasmodium parasites. It is particularly effective against the Plasmodium falciparum species, which is responsible for the most severe forms of malaria. Halofantrine is known for its ability to clear parasitemia rapidly, but its use is limited due to concerns about cardiotoxicity and drug interactions.

Pharmacology

Halofantrine is a member of the phenanthrene methanol class of antimalarial drugs. It works by interfering with the parasite's ability to digest hemoglobin, which is essential for its survival within the red blood cells of the host. The drug is administered orally and is absorbed in the gastrointestinal tract.

Mechanism of Action

Halofantrine acts by inhibiting the polymerization of heme into hemozoin, a process that is crucial for the detoxification of free heme, which is toxic to the parasite. By preventing this polymerization, halofantrine causes an accumulation of toxic heme, leading to the death of the parasite.

Pharmacokinetics

The absorption of halofantrine is highly variable and is significantly increased when taken with food, particularly fatty meals. This can lead to unpredictable plasma concentrations and potential toxicity. The drug is metabolized in the liver by the cytochrome P450 enzyme system, primarily CYP3A4, and is excreted in the bile and urine.

Clinical Use

Halofantrine is used primarily in the treatment of uncomplicated malaria caused by Plasmodium falciparum. It is often reserved for cases where other antimalarial drugs, such as chloroquine or mefloquine, are ineffective due to resistance.

Dosage and Administration

The typical dosage regimen involves administering halofantrine in three doses, each six hours apart. This schedule is designed to maximize the drug's efficacy while minimizing the risk of adverse effects.

Adverse Effects

The most significant adverse effect associated with halofantrine is its potential to cause cardiac arrhythmias, particularly QT interval prolongation. This can lead to serious complications such as torsades de pointes and sudden cardiac death. Other side effects may include gastrointestinal disturbances, headache, and dizziness.

Drug Interactions

Halofantrine should not be co-administered with other drugs that prolong the QT interval or with drugs that inhibit CYP3A4, as these interactions can increase the risk of cardiotoxicity. Patients should be monitored closely for any signs of cardiac dysfunction.

Related Pages

• Malaria
• Antimalarial medication
• Plasmodium falciparum
• Cardiotoxicity